Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 73-79

  Lee, Jee Young ^a   Cho, Jinwhan ^b   Lee, Eun Kyung ^c   Park, Sung Sup ^c   Jeon, Beom S ^c,d  

^a Seoul National University Boramae Hospital   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Diphasic dyskinesia; Dopamine receptor D3; Genetic susceptibility; Parkinson's disease

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIPHASIC DYSKINESIA; DISEASE DURATION; DNA POLYMORPHISM; DYSKINESIA; FEMALE; FOLLOW UP; GENDER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; KOREAN MEDICINE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PEAK DOSE DYSKINESIA; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COHORT STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROBABILITY; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 79951485860     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23400     Document Type: Article

References (34)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47 (Suppl. 1): S2-S11.
2. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005; 20 (S11): S11-S16.
3. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007; 83: 384-388.
4. Marconi RM, Lefebvre-Caparros D, Bonnet A-M, et al. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12.
5. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-931.
6. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379-1389.
7. Krack P, Pollak P, Limousin P, et al. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity Brain 1999; 122: 1133-1146.
8. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008; 23 (Suppl 3): S570-S579.
9. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in levodopa induced dyskinesia. Nat Neurosci 2003; 6: 501-506.
10. Bézard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003; 9: 762-767.
11. Guigoni C, Aubert I, Li Q, et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord 2005; 11: S25-S29.
12. Ohtsuki T, Sakurai K, Dou H, et al. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol Psychiatry 2001; 6: 211-216.
13. Liou YJ, Wang YC, Chen JY, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 2007; 153: 271-275.
14. Lee JY, Lee EK, Lim JY, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson disease. Mov Disord 2009; 24: 1803-1810.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
16. Heinz A, Jones DW, Mazzanti C, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47: 643-649.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
18. Sassin JF, TAub S, Weitzman ED. Hyperkinesia and changes in behavior produced in normal monkeys by levodopa. Neurology 1972; 22: 1122-1125.
19. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997; 94: 3363-3367.
20. Bordet R, Ridray S, Schwartz JC, Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopaine-lesioned rats. Eur J Neurosci 2000; 12: 2117-2123.
21. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization. Nature 2001; 411: 86-89.
22. Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 140-144.
23. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225: 1068-1072.
24. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
25. Steen VM, Lovile R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-145.
26. Sethi KD, Morgan JC. Drug-induced movement disorders. In: Jankovic J, Tolosa E, editors. Parkinson's disease & movement disorders, Fifth ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p 401.
27. Kaiser R, Hofer A, Grapengiesser A, et al. Levodopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750-1755.
28. Paus S, Gadow F, Knapp M, et al. Motor complications in patients from the German competence network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov Disord 2009; 24: 1080-1084.
29. Arning L, Saft C, Wieczorek S, et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 2007; 122: 175-182.
30. Hong CJ, Yu YW, Lin CH, et al. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet 2001; 11: 219-222.
31. Pohjalainen T, Rinne JO, Någren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260.
32. Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesia in PD. Neurology 1999; 53: 1425-1430.
33. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005; 62: 601-605.
34. Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001; 56: 1757-1759.